Cue Biopharma Inc
CUE0.268USD
-0.074-21.58%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
20.86MMarket Cap
LossP/E TTM
More Details of Cue Biopharma Inc Company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Cue Biopharma Inc Info
Ticker SymbolCUE
Company nameCue Biopharma Inc
IPO dateJan 02, 2018
CEOAzam (Usman)
Number of employees41
Security typeOrdinary Share
Fiscal year-endJan 02
Address40 Guest Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02135
Phone16179492680
Websitehttps://www.cuebiopharma.com/
Ticker SymbolCUE
IPO dateJan 02, 2018
CEOAzam (Usman)
Company Executives of Cue Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
28.00K
--
Mr. Patrick Verheyen
Mr. Patrick Verheyen
Independent Director
Independent Director
8.17K
--
Dr. Usman (Oz) Azam, M.D.
Dr. Usman (Oz) Azam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jill Broadfoot
Mr. Jill Broadfoot
Director
Director
--
--
Dr. Daniel G. (Dan) Baker, M.D.
Dr. Daniel G. (Dan) Baker, M.D.
Interim Chief Development Officer
Interim Chief Development Officer
--
--
Mr. Pasha Sarraf
Mr. Pasha Sarraf
Independent Director
Independent Director
--
--
Ms. Lucinda Warren
Ms. Lucinda Warren
Chief Business officer
Chief Business officer
--
--
Mr. Colin G. Sandercock, J.D.
Mr. Colin G. Sandercock, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Dr. Peter A. Kiener, Ph.D.
Dr. Peter A. Kiener, Ph.D.
Independent Director
Independent Director
--
--
Dr. Pamela Garzone, Ph.D.
Dr. Pamela Garzone, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
28.00K
--
Mr. Patrick Verheyen
Mr. Patrick Verheyen
Independent Director
Independent Director
8.17K
--
Dr. Usman (Oz) Azam, M.D.
Dr. Usman (Oz) Azam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jill Broadfoot
Mr. Jill Broadfoot
Director
Director
--
--
Dr. Daniel G. (Dan) Baker, M.D.
Dr. Daniel G. (Dan) Baker, M.D.
Interim Chief Development Officer
Interim Chief Development Officer
--
--
Mr. Pasha Sarraf
Mr. Pasha Sarraf
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bleichroeder LP
8.66%
Catalytic Wealth RIA, LLC
4.36%
The Vanguard Group, Inc.
3.86%
Geode Capital Management, L.L.C.
1.02%
Boothbay Fund Management, LLC
0.78%
Other
81.33%
Shareholders
Shareholders
Proportion
Bleichroeder LP
8.66%
Catalytic Wealth RIA, LLC
4.36%
The Vanguard Group, Inc.
3.86%
Geode Capital Management, L.L.C.
1.02%
Boothbay Fund Management, LLC
0.78%
Other
81.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor
19.21%
Investment Advisor/Hedge Fund
2.85%
Research Firm
0.50%
Hedge Fund
0.35%
Individual Investor
0.34%
Venture Capital
0.02%
Other
76.73%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
162
18.07M
28.38%
--
2025Q3
169
18.07M
29.68%
+719.03K
2025Q2
176
17.35M
22.56%
+5.92M
2025Q1
178
11.43M
29.61%
-6.87M
2024Q4
181
11.80M
29.03%
-2.11M
2024Q3
178
13.92M
29.55%
+70.57K
2024Q2
188
13.86M
40.48%
-2.61M
2024Q1
212
16.48M
40.45%
-3.20M
2023Q4
220
15.00M
39.38%
+824.81K
2023Q3
225
14.16M
42.40%
+185.59K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bleichroeder LP
6.82M
8.87%
+1.82M
+36.46%
Jun 30, 2025
Catalytic Wealth RIA, LLC
3.33M
4.34%
+3.33M
--
Jun 30, 2025
The Vanguard Group, Inc.
3.19M
4.15%
+871.48K
+37.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
692.17K
0.9%
-1.72K
-0.25%
Jun 30, 2025
Robertson Stephens Wealth Management, LLC
478.50K
0.62%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
446.59K
0.58%
-113.22K
-20.22%
Jun 30, 2025
BofA Global Research (US)
324.58K
0.42%
+233.00
+0.07%
Jun 30, 2025
Advisory Research, Inc.
257.23K
0.33%
--
--
Jun 30, 2025
Renaissance Technologies LLC
133.46K
0.17%
+96.52K
+261.24%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
View more
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cue Biopharma Inc?
The top five shareholders of Cue Biopharma Inc are:
Bleichroeder LP holds 6.82M shares, accounting for 8.87% of the total shares.
Catalytic Wealth RIA, LLC holds 3.33M shares, accounting for 4.34% of the total shares.
The Vanguard Group, Inc. holds 3.19M shares, accounting for 4.15% of the total shares.
Geode Capital Management, L.L.C. holds 692.17K shares, accounting for 0.90% of the total shares.
Robertson Stephens Wealth Management, LLC holds 478.50K shares, accounting for 0.62% of the total shares.
Bleichroeder LP holds 6.82M shares, accounting for 8.87% of the total shares.
Catalytic Wealth RIA, LLC holds 3.33M shares, accounting for 4.34% of the total shares.
The Vanguard Group, Inc. holds 3.19M shares, accounting for 4.15% of the total shares.
Geode Capital Management, L.L.C. holds 692.17K shares, accounting for 0.90% of the total shares.
Robertson Stephens Wealth Management, LLC holds 478.50K shares, accounting for 0.62% of the total shares.
What are the top three shareholder types of Cue Biopharma Inc?
The top three shareholder types of Cue Biopharma Inc are:
Bleichroeder LP
Catalytic Wealth RIA, LLC
The Vanguard Group, Inc.
Bleichroeder LP
Catalytic Wealth RIA, LLC
The Vanguard Group, Inc.
How many institutions hold shares of Cue Biopharma Inc (CUE)?
As of 2025Q4, 162 institutions hold shares of Cue Biopharma Inc, with a combined market value of approximately 18.07M, accounting for 28.38% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.30%.
What is the biggest source of revenue for Cue Biopharma Inc?
In --, the -- business generated the highest revenue for Cue Biopharma Inc, amounting to -- and accounting for --% of total revenue.
